Changeflow GovPing Pharma & Drug Safety Heteroaryl Heterocyclic Compounds and Uses Ther...
Routine Notice Added Final

Heteroaryl Heterocyclic Compounds and Uses Thereof, Hutchison Medipharma

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

EPO published patent application EP4214206A1 for Hutchison Medipharma Limited covering heteroaryl heterocyclic compounds and their therapeutic uses. The patent application covers compounds classified under C07D 471/04 and C07D 487/04 with pharmaceutical applications including anticancer (A61P 35/00) and immunomodulator (A61P 37/00) indications. The application designates all major EPC contracting states across the EU and EFTA.

What changed

EPO published patent application EP4214206A1 for heteroaryl heterocyclic compounds filed by Hutchison Medipharma Limited. The application claims compounds effective as anticancer agents (A61P 35/00) and immunomodulators (A61P 37/00), with priority classifications in heterocyclic chemistry (C07D 471/04, C07D 487/04) and pharmaceutical compositions (A61K 31/4985, A61K 31/381). Designated states include all major European Economic Area countries.

Pharmaceutical companies developing competing heterocyclic therapeutics must consider this patent in freedom-to-operate analyses. Generic drug manufacturers targeting the EU market should monitor the prosecution history for potential design-around opportunities during the nine-month opposition period following publication.

What to do next

  1. Monitor for patent validation in target European markets
  2. Review freedom-to-operate for related compound development

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF

Publication EP4214206A1 Kind: A1 Apr 01, 2026

Applicants

Hutchison Medipharma Limited

Inventors

DAI, Guangxiu, XIAO, Kun

IPC Classifications

C07D 471/04 20060101AFI20240905BHEP C07D 471/14 20060101ALI20240905BHEP C07D 487/04 20060101ALI20240905BHEP A61K 31/4985 20060101ALI20240905BHEP A61K 31/381 20060101ALI20240905BHEP A61P 35/00 20060101ALI20240905BHEP A61P 37/00 20060101ALI20240905BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4214206A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication Drug compound protection Therapeutic patent claims
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!